Table 1 Guideline questions and outcomes of importance
Question | Critical outcomes | Important outcomes |
|---|---|---|
1. Should tixagevimab + cilgavimab be recommended for pre-exposure prophylaxis in people at high risk of developing severe COVID-19? | Symptomatic COVID-19 Adverse event with death | Serious adverse event |
2. Should certain (see bottom of table) monoclonal antibodies be recommended for outpatients with mild COVID-19?a | Hospitalisation Death | Serious adverse event |
3. Should molnupiravir be recommended for outpatients with mild COVID-19? | Hospitalisation Death | Serious adverse event |
4. Should nirmatrelvir/ritonavir be recommended for outpatients with mild COVID-19? | Hospitalisation Death | Serious adverse event |
5. Should remdesivir be recommended for outpatients with mild COVID-19? | Hospitalisation Death | Serious adverse event |
6. Should hydroxychloroquine or chloroquine be recommended for outpatients with mild COVID-19? | Hospitalisation Death | Serious adverse event |
7. Should ivermectin be recommended for outpatients with mild COVID-19? | Hospitalisation Death | Serious adverse event |
8. Should remdesivir be recommended for hospitalised patients with severe COVID-19? | Mechanical ventilation Death | Serious adverse event |
9. Should baricitinib be recommended for hospitalised patients with severe COVID-19? | Mechanical ventilation Death | Serious adverse event |
10. Should tocilizumab be recommended for hospitalised patients with severe COVID-19? | Mechanical ventilation Death | Serious adverse event |